BioCryst Pharmaceuticals plans to introduce products for an expanding lineup of treatments today but Thursday’s latest financial results points to further sales for its Orladeyo which the company says is on target to hit $1 billion in annual sales.
Read More
Earnings news out early Thursday before the markets opened was not good news for CommScope, Chimerix and Biocryst. Here are the details.
Read More
BioCryst Pharmaceuticals on Wednesday reported a loss of $53.3 million in its first quarter, but the company’s CEO says its top product is on its way to a billion dollar a year sales target.
Read More
BioCryst Pharmaceuticals has named longtime board member Nancy Hutson to replace the late Bob Ingram as its board chairman.
Read More
To those unfamiliar with the challenges of living with a rare disease, an “ordinary life” may sound like a low bar to set. But for many impacted by a rare disease, a sense of ordinary is a goal once thought unattainable. But, happily, progress is being made. And patients participating in clinical trials are crucial to that progress.
Read More
BioCryst Pharmaceuticals delivers more revenue but also larger losses than expected in its latest quarter. However, there are signs of hope.
Read More
The newly launched Museum of Life and Science Sparks Afterschool Program is powered by BioCryst, an educational collaboration between the organizations we lead: the Museum of Life and Science, and BioCryst. Let’s take a look.
Read More
At BioCryst, women in leadership create a supportive community and ways to pave the trail for others.
Read More
Durham-based BioCryst, which discovers and develops medicines to treat rare diseases, said the U.S. Food and Drug Administration has granted orphan drug designation for its experimental therapy to treat fibrodysplasia ossificans progressive (FOP).
Read More
